Paying users zone. Data is hidden behind 
.
Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Regeneron Pharmaceuticals Inc. (REGN)
Income Statement
Low level of difficulty
The income statement presents information on the financial results of a company’s business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Regeneron Pharmaceuticals Inc., consolidated income statement
US$ in thousands
Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).
| Income statement item | Description | The company |
|---|---|---|
| Revenues | Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. | Regeneron Pharmaceuticals Inc.’s revenues increased from 2016 to 2017 and from 2017 to 2018. |
| Income from operations | The net result for the period of deducting operating expenses from operating revenues. | Regeneron Pharmaceuticals Inc.’s income from operations increased from 2016 to 2017 and from 2017 to 2018. |
| Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Regeneron Pharmaceuticals Inc.’s income before income taxes increased from 2016 to 2017 and from 2017 to 2018. |
| Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Regeneron Pharmaceuticals Inc.’s net income increased from 2016 to 2017 and from 2017 to 2018. |